|
September 2010
|
Neurotez will participate in the Translational Neuroscience 2010 conference in Frankfurt, Germany, 27-28 October 2010----------
see interview by Dr. Nikolaos Tezapsidis Click here
|
| |
|
August 2010
|
UBIFRANCE Biotech Team has selected Neurotez to give a presentation during the FRENCH BIOTECH TOUR 2010. This will take place in Philadelphia, PA, on Septmber 14, 2010
|
| |
|
August 2010
|
Neurotez has been chosen as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Recognition will be presented at the Gala Awards Ceremony on November 17 at the Hilton New Brunswick, NJ.
|
| |
|
May 2010
|
Nikolaos Tezapsidis, President & CEO will be presenting at BioNJ's 2010 BioPartnering Conference to be held 14-15 June at the Westin Princeton at Forrestal Village, Princeton, NJ
|
| |
|
May 2010
|
Dr. Steven Jacobsen, VP in Translational Biology, Proteostasis Therapeutics, Inc. has joined Neurotez's Advisory Board. Dr. Jacobsen has extensive experience in drug research and development in CNS disorders, particularly Alzheimer's disease. As a Director at Wyeth he led numerous preclinical programs, that reached the stage of clinical testing.
|
| |
|
April 2010
|
Neurotez, Inc. launched the manufacturing of its own Leptin product.
|
| |
|
Dec 2009
|
Neurotez, Inc. will be presenting at the Biotech Showcase 2010 in San Francisco (Jan 12-13, 2010)
|
| |
|
Dec. 16, 2009
|
Press Release-BUSINESSWIRE----------
New Study Published in JAMA Supports Neurotez Plans for the Development of Leptin as a Therapy for AD
Click here for the press release
|
| |
|
Oct. 14 2009
|
Dr. J. Wesson Ashford, MD, PhD (Clinical Professor at Stanford University and a Senior Scientist at the Palo Alto VA) will be presenting at the the CTAD (Clinical Trials in Alzheimer's disease) meeting in Las Vegas on Oct 30th, 2009. The title of his talk is: "Testing a Leptin product as a novel therapy for Alzheimer's disease"
|
| |
|
October 2009
|
New studies in collaboration with Case Western Reserve University confirm that Leptin treatment ameliorates pathological and behavioral changes in transgenic animals of Alzheimer's diesase.
|
| |
|
October 2009
|
Neurotez will be presenting at
"The 2009 Life Sciences and Healthcare Venture Summit"
Date: Oct 27, 2009
Location: Digital Sandbox, New York City
|
| |
|
8/03/2009
|
Press Release (BUSINESSWIRE):
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20090803005337&newsLang=en
|
| |
|
7/30/ 2009
|
FOR IMMEDIATE RELEASE:
Neurotez is awarded a multi-million phase II SBIR grant for the clinical development of Leptin for Alzheimer's disease. More details will be provided in a press release.
|
| |
|
April 2009
|
A recent review article in the Journal of Alzheimer's disease http://www.j-alz.com/, in a special issue focusing on the link between Diabetes and Alzheimer's disease (http://www.j-alz.com/issues/16/vol16-4.html), describes the rationale and most recent findings supporting the use of Leptin as a Novel Therapeutic strategy for Alzheimer's disease (http://iospress.metapress.com/content/3375752606620632/). Please email jjohnston@neurotez.com for reprint request.
|
| |
|
February 2009
|
Steven Greco, Principal Scientist at Neurotez, Inc. will be presenting at CHI's Inaugural: Targeting Alzheimer's with Novel Therapeutics, Delivering Preclinical to Clinical Candidates for an Unmet Medical Need, June 10-11, 2009 in Philadelphia, PA CHI's Inaugarual :Targeting Alzheimer's with Novel Therapeutics
http://www.worldpharmacongress.com/dload_alz.asp
|
| |
|
11/30/2008
|
2008 Mid-Atlantic Capital (MAC) Conference
BRIDGEWATER, N.J.--(BUSINESS WIRE)—Neurotez, Inc., a company developing therapies for Alzheimer’s disease, is proud to announce that it has been selected as a Featured Company for the 2008 MAC Conference. A Presentation will be held on Wednesday, December 3 by Chief Executive Officer, Dr. Nikolaos Tezapsidis on 2:45pm in Life Sciences Room 201ABC at the Pennsylvania Convention Center, Philadelphia, PA.
|
| |
|
November 2008
|
Nikolaos Tezapsidis will present for Neurotez at the Biotech2008 Symposium, held at the Loews Philadelphia Hotel on November 10-11, 2008 http://www.biotech2008.org/content/view/171/190/
|
| |
|
October 2008
|
Nikolaos Tezapsidis, President & CEO of Neurotez will present at the 4th Neurodegenerative Disease Drug Discovery Conference in Philadelphia, PA on October 10th.
|
| |
|
September 2008
|
New peer review article from work at Neurotez in collaboration with Case Western Reserve University and Stanford University has been accepted in the "Biochemical and Biophysical Research Communications" describing novel findings about leptin and its ability to modulate tau phosphorylation.
|
| |
|
June 2008
|
Michael Hoy joins Neurotez, Inc. as Director of Regulatory Affairs.
|
| |
|
May 2008
|
We are excited with the addition of Professor George Perry, also Dean at the University of Texas at San Antonio to the Board of Directors of Neurotez, Inc. Dr. Perry is an expert in Alzheimer's disease and has made pioneering contributions to the understanding of disease mechanisms.
|
| |
|
January 2008
|
Neurotez will be presenting at the 10th Annual BIOCEO & Investor Conference on Feb 13th, 2008 at the Waldorf=Astoria, in New York City
|
| |
|
December 2007
|
Neurotez will be receiving a grant from the NJ Commission of Science and Technology to further support the program in Leptin and AD.
|
| |
|
11/29/2007
|
| Dr. J.Wes Ashford joins Neurotez as the chief medical officer |
|
|
| |
|
11/1/ 2007
|
James Lynch, PhD, MBA, joins Neurotez as the chief business officer
|
| |
|
5/31/2007
|
Neurotez signs lease agreement for NJEDA lab space in North Brunswick, NJ, beginning June 1st.
|
| |
|
5/4/2007
|
Neurotez, Inc. is awarded a $0.7M milestone NIH grant. "We are very excited. Grants provide non-dilutive capital and validation of our technology by field experts. While we will continue seeking grant moneys from federal and local agencies, we foresee that our success will attract the attention of the investment community. Our strategy towards the clinical development of our main product for Alzheimer's disease and the expansion of our pipeline remains on target", commented Dr. Nikolaos Tezapsidis, President and CEO.
|
| |
|
3/12/2007
|
| Peter J. Dussias, MBA joins the advisory board of Neurotez |
|
|
| |
|
February 2007
|
Neurotez SBIR grant application to the NIH was reviewed by the Council.
|
| |
|
November 2006
|
Neurotez SBIR grant application to the NIH was reviewed by a SRG and received favorable score
|
| |
|
10/17/2006
|
Neurotez, Inc. participated at the Biotech2006 in Philadelphia, PA. Dr. Mark Smith, CSO presented our program at the Hot Topics in Science Session with the title: "Therapeutic Interventions for Alzheimer's disease" http://www.biotech2006.org
|
| |
|
6/18/2006
|
|
| |
|
6/13/2006
|
Neurotez, Inc. presented at the BioVentureForum East 2006 in Jersey City, NJ (6/12-14/2006)
|
| |
|
5/12/2006
|
Neurotez, Inc. was interviewed by Ian Roberts, senior analyst at Wall Street Reporter
|
| |
|
4/18/2006
|
Neurotez, Inc. presented at the "New Jersey Biotechnology Venture Idol 2006", organized by BCNJ and held at Princeton University.
|
| |
|
2/14/2006
|
| Neurotez, Inc. announces the formation of its Scientific Advisory Board, co-chaired by two internationally renowned Clinician Scientists, Dr. Christos Mantzoros, MD, DSc (Harvard University) and Dr. J. Wesson Ashford, MD, PhD (Stanford University). |
|
|
| |
|
10/14/2005
|
Neurotez was incorporated as a private company in Delaware.
|
| |
|
|
Linking Leptin to AD, Alzforum, Dec 2004 http://www.alzforum.org/new/detail.asp?id=1121
|
| |
|
|
Obesity-related Leptin regulates Alzheimer's Abeta, FASEB J 18, 1870-1878, 2004
|
| |
|
|
Axonal transport hypothesis moves on to implicate presenilin: Alzheimer research forum discussion, Journal of Alzheimer's Disease 6, 537-545, 2004
|
| |
|
|
Good and Bad News about an Alzheimer's Disease target, In Vivo, Jun 2003 http://www.cumc.columbia.edu/news/in-vivo/Vol2_Iss11_jun23_03/alzheimer-disease.html
|
| |
|
|
Microtubular interactions of presenilin direct kinesis of Abeta peptide and its precursors, FASEB J, 17, 1322-1324, 2003
|
| |
|
|
Altered binding of mutated Presenilin with cytoskeletal-interacting proteins, FEBS Letters, 465, 53-58, 2000
|
| |
|
|
Steven Greco, Principal scientist will present new findings at the CHI's Targeting Alzheimer's with Novel Therapeutics
Delivering Preclinical to Clinical Candidates for an Unmet Medical Need
June 10-11, 2009 | Philadelphia, PA
http://www.worldpharmacongress.com/dload_alz.asp
|
| |
|
|
|
| |
|
321
|
|
| |
|
|
|
| |
